Analyst Serge Belanger works at NEEDHAM and is focused on the Healthcare sector with 345 price targets and ratings documented since 2009 spanning on 26 stocks. Analyst's average stock valuation to be materialised ratio is 49.68% with an average time for price targets to be met of 288.32 days.
Most recent stock forecast was given on HRTX, Heron Therapeutics, Inc at 09-Nov-2022.
Serge Belanger best performing recommendations are on GRAY.
The best stock recommendation documented was for KALV at 1/26/2021. The price target of $32 was fulfilled within 14 days with a profit of $15.65 (95.72%) receiving and performance score of 68.37.
Average potential price target upside